<DOC>
	<DOC>NCT00299390</DOC>
	<brief_summary>The purpose of this study is to determine whether the study drug is effective and safe in the first line treatment of patients with small cell lung cancer</brief_summary>
	<brief_title>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Histologically or cytologically proven Smallcell lung cancer (SCLC) Stage of extensive disease defined by the presence of distant metastases At least 1 unidimensionally measureable lesion WHO performance status 0 to 1 No previous SCLCrelated chemotherapy No previous SCLCrelated surgery No previous radiotherapy (excepting for brain metastasis) Adequate function of major organs and systems Nervous system No Grade 2 or greater peripheral neuropathy Cardiovascular: No symptomatic congestive heart failure No unstable angina pectoris No arrythmia needing continuous treatment No other uncontrolled concurrent illness Superior vena cava syndrome or obstruction of any vital structure Untreated malignant hypercalcemia Pleural effusion as the only manifestation of disease Extensive disease amenable to radiation therapy Symptomatic brain metastases requiring whole brain irradiation Any concomitant malignancy excepting nonmelanoma skin cancer or carcinoma in situ of the cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Sagopilone</keyword>
	<keyword>Epothilone</keyword>
	<keyword>SCLC</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>